Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172 · View on ClinicalTrials.gov ↗
Study Summary
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Conditions Studied
Interventions
- DRUG Eptinezumab
Study Locations (20)
Florida
- NW FL Clinical Research Group, LLC — Gulf Breeze
- AGA Clinical Trials — Hialeah
- Axcess Medical Research — Loxahatchee Groves
- University of South Florida — Tampa
Michigan
- Michigan Head Pain and Neurological Institute — Ann Arbor
- Michigan State University - Department of Neurology — East Lansing
- Helen Devos Childrens' Hospital - PIN — Grand Rapids
Connecticut
- Yale University School of Medicine — New Haven
- Ki Health Partners LLC DBA New England Institute for Clinical Research — Stamford
New York
- Dent Neurosciences Research Center Incorporated — Amherst
- True North Neurology — Commack
Ohio
- Childrens Hospital Medical Center of Akron — Akron
- Cincinnati Children's Hospital Medical Center - PIN — Cincinnati
Kentucky
- University of Kentucky — Lexington
Maryland
- University of Maryland School of Medicine — Baltimore
North Carolina
- OnSite Clinical Solutions, LLC - Randolph Rd - Charlotte — Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05164172
The ClinicalTrials.gov registry entry for NCT05164172 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 17 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention — of which Eptinezumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05164172 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Michigan, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05164172 about?
NCT05164172 is a clinical study titled "A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine". The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
What is the current status of trial NCT05164172?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2021-12-01. Estimated completion is 2028-04-30.
What conditions does trial NCT05164172 study?
This clinical trial studies the following conditions: Migraine. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05164172?
The interventions under investigation include: Eptinezumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05164172?
This trial is sponsored by H. Lundbeck A/S, which has 17 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05164172 being conducted?
This trial has 20 study locations across Connecticut, Florida, Kentucky, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.